Open AccessIs There a Dose-Response Relationship? Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Treatment in Neovascular Age-Related Macular Degeneration
Author(s) -
Reut Shor,
Adiel Barak,
Anat Loewenstein,
Marganit Shahar-Gonen,
Michaella Goldstein,
Ronni Gamzu,
Dinah Zur
Publication year - 2022
Publication title -
ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.639
H-Index - 60
eISSN - 1423-0267
pISSN - 0030-3755
DOI - 10.1159/000525653
Subject(s) - medicine , bevacizumab , macular degeneration , choroidal neovascularization , group b , gastroenterology , ophthalmology , chemotherapy
The aim of study was to explore the dose-response relationship of anti-vascular endothelial growth factor (VEGF) agents, with bevacizumab as 1st-line treatment, on the visual-acuity (VA) outcome during the first year of treatment in neovascular AMD (nAMD) patients in real-life conditions.